Building on successful PD-1 pact, Eli Lilly licenses diabetes drug to Chinese partners at Innovent
Eli Lilly is expanding its partnership with China’s Innovent in a deal involving a diabetes drug sitting in its Phase I reserves.
The two companies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
